A clinical trial was unable to prove the efficacy of the antiparasitic medicine ivermectin against coronavirus variants, according to Japanese drugmaker Kowa Co., which has indicated that it will no longer seek approval for the drug as a COVID-19 treatment.
The central government on Tuesday added at least 34 drugs to the National List of Essential Medicines (NLEM) 2022 and dropped as many as 26 from the previous list. The new list contains a total 384 drugs in comparison to 376 in NLEM 2015. The NLEM 2022 comprises 384 drugs across 27 categories.
Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to market Ivermectin cream, 1%, according to a company statement.
Zydus Lifesciences Limited has received final approval from the United States Fo ..
Zydus Pharmaceuticals Generic Ivermectin Receives Approval in the U.S.
NIH’s Active-6 investigators randomized mild to moderately ill COVID outpatients to placebo or ivermectin 0.4 mg/kg for 3 days COVID in an attempt to see if ivermectin was effective for early COVID. The dose used was felt to be acceptable by all for the alpha variant which was dominant at the time study planning began. The study ultimately treated a patient population heavily infected with delta (70%) for which the ivermectin dose was much too low, however, the study investigators never changed the dose or added another arm with a higher dose.
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its Phase 1 clinical trial investigating oral biweekly ivermectin (LYN-163) to fight malaria.
Boyden Gray & Associates PLLC -- Today, a group of doctors filed a lawsuit against the Department of Health and Human Services, Xavier Becerra in his ...
A study aimed at determining the efficacy and safety of the antiparisitic drug ivermectin on COVID-19 patients has been terminated, Science and Technology Secretary Fortunato de la Peña said on Friday.
(Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.